Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

MERCK KGAA

(MRK)
  Report
Real-time Estimate Quote. Real-time Estimate Tradegate - 10/20 02:23:38 pm
124.875 EUR   +0.46%
10/16Physiomics Wins Contracts With Existing Customers
DJ
10/15MERCK : Global Head of R&D for Healthcare to Retire
DJ
10/15Global Glycobiology Market to Rise at 14.64% between 2020 and 2027
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Merck : to Invest EUR59 Million to Expand Pharmaceutical Manufacturing at US Facility

share with twitter share with LinkedIn share with facebook
09/09/2020 | 10:56am EDT

By Cecilia Butini

 

Merck KGaA said Wednesday that it would invest 59 million euros ($69.5 million) in expanding its manufacturing capabilities, and capacity for high-potent active pharmaceutical ingredients and antibody-drug conjugates at its U.S. facility near Madison, Wisc.

The German pharmaceuticals and chemicals company said the investment would allow manufacturing of compounds for therapies which have the potential to treat cancer, and it would create roughly 50 full-time jobs starting in 2021.

Completion of the expansion--which consists of a 6,500-square-meter commercial building--is expected by mid-2022, the company said.

 

Write to Cecilia Butini at cecilia.butini@wsj.com

 


share with twitter share with LinkedIn share with facebook
All news about MERCK KGAA
10/16Physiomics Wins Contracts With Existing Customers
DJ
10/15MERCK : Global Head of R&D for Healthcare to Retire
DJ
10/15Global Glycobiology Market to Rise at 14.64% between 2020 and 2027
AQ
10/13MERCK : Launches Cell and Gene Therapy Platform
DJ
10/13MERCK KGAA : Barclays withdraws its Sell rating
MD
10/12Merck KgaA Licenses Genome-Editing Technology to Two Companies
DJ
10/09MERCK : Precigen Shares Gain 20% as Germany's Merck Raises Stake
DJ
10/09MERCK : Raises Precigen Stake to 14.8% With Note Conversion
DJ
10/08MERCK : MilliporeSigma Celebrates Topping-Out Ceremony for New Membrane Producti..
AQ
10/07NOVARTIS : EU must wean itself off Asia for key drug ingredients
RE
More news
Financials
Sales 2020 17 314 M 20 474 M 20 474 M
Net income 2020 1 704 M 2 015 M 2 015 M
Net Debt 2020 10 875 M 12 860 M 12 860 M
P/E ratio 2020 30,5x
Yield 2020 1,07%
Capitalization 54 043 M 63 926 M 63 908 M
EV / Sales 2020 3,75x
EV / Sales 2021 3,47x
Nbr of Employees 57 523
Free-Float 29,7%
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 126,24 €
Last Close Price 124,30 €
Spread / Highest target 20,7%
Spread / Average Target 1,56%
Spread / Lowest Target -18,7%
EPS Revisions
Managers
NameTitle
Stefan Oschmann Chairman-Executive Board & CEO
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Christian Raabe Independent Member-Supervisory Board
Edeltraud Glänzer Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA17.99%63 662
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD123.45%21 848
KYOWA KIRIN CO., LTD.3.03%13 727
BETTA PHARMACEUTICALS CO., LTD.63.61%6 479
YUHAN CORPORATION28.12%3 389
RECIPHARM AB (PUBL)18.69%1 783